27% REVENUE GROWTH TO $71.1 Million
51% EBIT GROWTH TO $4.0 Million
52% EBITDA GROWTH TO $6.6 Million
62% EBITDAS GROWTH TO $8.7 Million
Conference Call Webcast Live Today at 1:30 pm Pacific/4:30 pm Eastern
BOTHELL, WA - April 25, 2011 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in bedside and point-of-care ultrasound, today reported financial results for the first quarter ended March 31, 2011.
Revenue for the first quarter of 2011 was $71.1 million, an increase of 27% compared to $56.0 million in the first quarter of 2010. Revenue from VisualSonics, Inc., acquired in June 2010, was $8.2 million for the quarter.
Foreign currency rates had a 2% favorable impact on first quarter revenue results.
FIRST QUARTER HIGHLIGHTS
EBITDAS, EBITDA and Operating Income (EBIT)
First Quarter Results
First quarter EBITDAS was $8.7 million or 12% of revenue, an increase of 62% over the prior year.
EBITDA was $6.6 million or 9% of revenue, an increase of 52% over the prior year.
EBIT was $4.0 million or 6% of revenue, an increase of 51% over the prior year.
EPS was $0.07 per share for the first quarter of 2011 versus $0.08 per share in 2010. SonoSite recognized an income tax expense of $0.7 million in 2011 compared to an income tax benefit of $1.0 million in the prior year.
"We finished the first quarter strong with the fifth consecutive quarter that our revenue growth has exceeded expectations," said Kevin M. Goodwin, SonoSite President and CEO. "We also saw positive trends and sustained growth in the hospital channel, fueling our confidence in the expansion of point-of-care visualization, which is significant as we prepare to roll-out our new product portfolio in the upcoming months. Our international business also performed well despite facing economic uncertainties and the challenges in Japan."
Mr. Goodwin continued, "Our newly acquired VisualSonics (VSI) business also had a solid quarter, contributing eight million dollars to the top line, in spite of delays in NIH research funding, which impacted revenue performance due to delays in the U.S. Government budget approval. Additionally, in the quarter, VSI launched the Vevo LAZR Photoacoustics Imaging system at the recent American Association of Cancer Research conference and received strong interest among researchers. We are confident that the photoacoustics technology will transform scientific discovery and extend beyond cancer research."
"We have seen positive secular momentum for five consecutive quarters and have become much more confident about the long-term opportunity for significant growth in point-of-care visualization," said Marcus Smith, SonoSite's CFO. "This, combined with the successful acquisition of VisualSonics, a robust pipeline of innovative new products, and thirteen years of practice creating and growing new markets indicates that we are in a unique position to significantly expand our reach and penetration."
Mr. Smith continued, "With this in mind, we are gearing up to go after this opportunity in a more aggressive manner. Management, with the full agreement of our Board of Directors, will be implementing a plan that involves a step-up in our growth investment over the next three years aimed at significantly increasing our value."
We are planning investments opportunities that will:
Reflecting the current investment strategy:
Mr. Smith continued, "As we have stated, profitable growth remains the key operating philosophy and revenue growth remains the key driver of long-term operating leverage. Our long-term objective is 15% revenue growth per year through 2014, which would take the company above the half billion dollar mark, and produce 20% operating margins."
This release includes discussions of EBITDA and EBITDAS; these are non-GAAP financial measures. SonoSite believes these measures are a useful complement to results provided in accordance with GAAP. "EBITDA" refers to operating income (EBIT) before depreciation and amortization. "EBITDAS" refers to operating income (EBIT) before depreciation, amortization and stock-based compensation.
Conference Call Information
SonoSite will hold a conference call on April 25th at 1:30 pm PT/4:30 pm ET. The call will be broadcast live and can be accessed via www.sonosite.com/company/investors. A replay of the audio webcast will be available beginning April 25th at 5:30 pm PT and will be available until May 9th at 11:59 pm PT by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 2602385 is required to access the replay. The call will also be archived on SonoSite's website.
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in bedside and point-of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound technology and impedance cardiography equipment. Headquartered near Seattle, the company is represented by fourteen subsidiaries and a global distribution network in over 100 countries. SonoSite's small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care.
Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release are "forward-looking statements" for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to our future financial condition and results of operations and statements regarding planned product launches and the potential market opportunity for these products. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance, are based on potentially inaccurate assumptions and are subject to known and unknown risks and uncertainties, including, without limitation, the risk that we do not achieve the financial results that we expect, the risk we are unable to launch our new products as and when expected, the risk that our existing and new products do not achieve market success and the other factors contained in Item 1A. "Risk Factors" section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.